Longitudinal Analysis of Mesopic Microperimetry in a Phase II Trial Evaluating Minocycline for Geographic Atrophy

• DOI: 10.1016/j.xops.2025.100783
• Publication Date: 2025-04-03T19:27:58Z
• Authors: Thilaka Arunachalam; Maria Abraham; Christine Orndahl; Supriya Menezes; Souvick Mukherjee; Cameron Duic; Minali Prasad; Fares Siddig; Sunil Bellur; Alisa T. Thavikulwat; Clare Bailey; SriniVas R. Sadda; Wai T. Wong; Emily Y. Chew; Brett G. Jeffrey; Tiarnán D.L. Keenan
• Keywords: Microperimetry; Geographic atrophy; Mesopic vision

To analyze mesopic microperimetry data from a recent phase II trial of minocycline for geographic atrophy (GA) possible efficacy on the change in visual function and, absence efficacy, to perform longitudinal analyses as natural history study. Phase II, prospective, single-arm, nonrandomized trial. After 9-month run-in phase, participants began oral 100 mg twice daily 3 years. Individuals with GA ≥1 eye. Participants underwent at baseline, month 3, and every 6 months thereafter, using custom T-shaped test pattern. Rates parameters were compared between 24-month treatment by linear spline regression. The mean macular responding sensitivity; perilesional extralesional number absolute relative scotomatous loci. Thirty study eyes 30 (mean age 74.1 years) follow-up 27.4 months). For 5 parameters, no significant difference rate phases was observed. 2 -0.74 decibels (dB)/year (standard error [SE] 0.85; P = 0.39) sensitivity, -0.30 dB/year (SE 0.72) 1.23 1.01; 0.22) -0.02 0.01; 0.31) transformed sensitivity. incidence ratios 1.17 0.11; 0.14) loci 0.73 0.004) results do not appear consistent clinically meaningful effect decline progression. This is previous corresponding structural data. findings demonstrate advantages disadvantages different parameters. optimal testing patterns represent trade-off greater sensitivity vs. risk floor/ceiling effects, regional averages providing useful compromise. may provide insights guide development end points clinical trials. Proprietary or commercial disclosure be found Footnotes Disclosures this article.